<DOC>
	<DOCNO>NCT02422121</DOCNO>
	<brief_summary>The study investigate effect treatment RNS60 21 day . Subjects ' FEV1 measure inhaled allergen challenge baseline 21 day treatment .</brief_summary>
	<brief_title>Effect RNS60 Late Phase Asthmatic Response Allergen Challenge</brief_title>
	<detailed_description>This randomize , placebo-controlled , parallel study approximately 32 male female subject mild asthma . Each subject receive either experimental placebo , administer nebulized dose twice daily 21 day .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Inclusion Criteria Subjects able willing give write informed consent ; Male female subject age 18 65 year inclusive . Subjects body weight ≥50 kg BMI 18.0 32.0 kg/m2 inclusive screening . Subjects steroidnaïve ( within 3 month screen oral corticosteroid within 28 day screen inhaled corticosteroid ) mild asthma satisfy Global Initiative Asthma ( GINA ) definition asthma , otherwise healthy . Male subject agree donate sperm first dose 3 month postlast dose . Male subject ( female partner child bear potential ) female subject child bear potential use two method highly effective contraception . Subjects nonsmokers exsmokers least 12 month le 10 pack year history . Subjects take concomitant antiasthma ( except shortacting inhaled β2agonists [ SABAs ] ) antiallergy medication least 6 week prior screen visit throughout study period . Antihistamines permit 7 day prior first screen visit . Prebronchodilator FEV1 ≥70 % predict normal value age , height sex screen prior first dose administration . Positive methacholine provocative concentration methacholine result 20 % fall FEV1 ( PC20 methacholine ) equal less 8 mg/mL screening . Documented allergy least one common allergen ( house dust mite , grass pollen allergens cat dander ) confirm skin prick test wheal ( ≥3 mm diameter ) . Historical data ( 1 year ) may use . Early asthmatic response ( FEV1 fall ≥ 20 % , 0 60 minute allergen challenge ) LAR ( FEV1 fall ≥15 % 3 8 hour challenge ) . Historical data 3 month enrolment may use . At admission FEV1 within 10 % predict FEV1 screening . If subject meet criterion first measurement 2 repeat permit . Exclusion Criteria Subjects conform inclusion criterion . Female subject pregnant , try become pregnant lactating . Subjects evidence history clinically significant hematological , renal , endocrine , pulmonary ( exclude mild asthma ) , gastrointestinal , cardiovascular ( include ischemic heart disease ) , hepatic , psychiatric , neurologic , severe allergy ( e.g . anaphylaxis angioedema ) . Worsening asthma 4 week precede screen visit ( require daily use nebulised β2agonists use long act β agonist [ LABA ] , require inpatient hospitalisation asthma control , require emergency room treatment , require systemic corticosteroid asthma control ) respiratory infection 4 week precede first screen visit prior randomization ( Day 1 ) . Use immunotherapy within 3 month prior first screen . Use nasal inhale corticosteroid , intraophthalmic corticosteroid , nasal , inhale , intraophthalmic cromolyn sodium nedocromil , leukotriene receptor antagonist ( zafirlukast , pranlukast , montelukast ) , 5lipoxygenase inhibitor ( zileuton ) within 28 day prior first screen throughout study . Subject LABA short long act antimuscarinics ( SAMA LAMA ) see also Section 6.8 . Concomitant disease condition could interfere conduct study , treatment could interfere conduct study , would , opinion Investigator , pose unacceptable risk patient study , include , limited , cancer , alcoholism , drug dependency abuse , psychiatric disease . History lifethreatening asthma , define asthma episode require intubation associate hypercapnoea , respiratory arrest hypoxic seizure . Symptomatic allergic rhinitis ( e.g. , hay fever ) , require treatment , screen predict symptomatic allergic rhinitis ( e.g. , hay fever ) time study , require treatment . History serious severe hypersensitivity allergy ( e.g. , anaphylaxis ) . History hypersensitivity budesonide excipients . Clinically significant abnormality physical examination laboratory test result ( include serum biochemistry , hematology urinalysis ) assess Investigator . Subjects received investigational drug clinical trial within 3 month , extend followup . Current diagnosis active epilepsy active seizure disorder require chronic therapy antiepileptic drug ( ) . Subjects vegans medical dietary restriction . Patients take concomitant treatment strong moderate inhibitor cytochrome P450 ( CYP ) 3A4 include oral/systemic ketoconazole , itraconozole , miconazole , clotrimazole , flucanazole , posaconazole , voriconazole , clarithromycin , erythromycin , ciprofloxacin , verapamil , diltiazem , indinavir , nelfinavir , saquinavir , ritonavir , amprenavir , lopinavir , atazanavir , darunavir cyclosporine . Patients take concomitant treatment inducer CYP3A4 : carbamazepine , dexamethasone , phenytoin , rifabutin , rifampin pioglitazone . Patients take concomitant treatment herbal medication/supplements St John 's Wort . Subjects supine systolic blood pressure ≥160 mmHg supine diastolic blood pressure ≥100 mmHg screen prior randomization . History alcohol abuse ( intake 24 unit alcohol per week ) drug addiction see positive screen drug abuse ( opiate , methadone , cocaine , amphetamine , cannabinoids , barbiturate , benzodiazepine ) positive alcohol test . Positive screen hepatitis B surface antigen , antibody hepatitis C virus antibody human immunodeficiency virus ( HIV 1 2 ) . Clinically significant abnormal 12lead ECG one demonstrate QTcB &gt; 450 m screening . Abnormal liver enzyme ( alanine aminotransferase &gt; 1.5x upper limit normal [ ULN ] total bilirubin &gt; 1.5x ULN ) . Subjects communicate reliably Investigator . Subjects unlikely cooperate requirement study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>